- Home
- TCRX vs FMN Comparison
TCRX vs FMN Comparison
Compare TCRX & FMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- FMN
- Stock Information
- Founded
- TCRX 2018
- FMN 2002
- Country
- TCRX United States
- FMN United States
- Employees
- TCRX N/A
- FMN N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- FMN Investment Managers
- Sector
- TCRX Health Care
- FMN Finance
- Exchange
- TCRX Nasdaq
- FMN Nasdaq
- Market Cap
- TCRX 91.7M
- FMN 83.3M
- IPO Year
- TCRX 2021
- FMN N/A
- Fundamental
- Price
- TCRX $1.91
- FMN $10.78
- Analyst Decision
- TCRX Strong Buy
- FMN
- Analyst Count
- TCRX 5
- FMN 0
- Target Price
- TCRX $9.40
- FMN N/A
- AVG Volume (30 Days)
- TCRX 208.8K
- FMN 22.8K
- Earning Date
- TCRX 08-12-2025
- FMN 01-01-0001
- Dividend Yield
- TCRX N/A
- FMN 3.86%
- EPS Growth
- TCRX N/A
- FMN N/A
- EPS
- TCRX N/A
- FMN N/A
- Revenue
- TCRX $6,961,000.00
- FMN N/A
- Revenue This Year
- TCRX $255.18
- FMN N/A
- Revenue Next Year
- TCRX N/A
- FMN N/A
- P/E Ratio
- TCRX N/A
- FMN N/A
- Revenue Growth
- TCRX N/A
- FMN N/A
- 52 Week Low
- TCRX $1.02
- FMN $9.09
- 52 Week High
- TCRX $6.23
- FMN $11.31
- Technical
- Relative Strength Index (RSI)
- TCRX 59.09
- FMN 62.84
- Support Level
- TCRX $1.73
- FMN $10.57
- Resistance Level
- TCRX $1.95
- FMN $10.68
- Average True Range (ATR)
- TCRX 0.12
- FMN 0.07
- MACD
- TCRX 0.01
- FMN -0.00
- Stochastic Oscillator
- TCRX 84.85
- FMN 100.00
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.